Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Pivotal Practice Views with the Oncology Brothers

Targeted Oncology's Pivotal Practice Views with the Oncology Brothers is a video series that focuses on recently-approved, practice-changing treatment options across tumor types.


3 experts are featured in this series.

FDA Approval of Tislelizumab

February 14th 2025

Read More


FDA Approval of Subcutaneous Nivolumab

FDA Approval of Subcutaneous Nivolumab

January 31st 2025

Read More


Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups

Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups

November 21st 2024

Read More


FDA Approval of Durvalumab (AEGEAN Trial)

FDA Approval of Durvalumab (AEGEAN Trial)

October 7th 2024

Read More


FDA Approval of Axatilimab (Phase 2 AGAVE-201)

FDA Approval of Axatilimab (Phase 2 AGAVE-201)

September 19th 2024

Read More


Onc Brothers - "FRESCO-2: Fruquintinib"

FRESCO-2: Fruquintinib

April 23rd 2024

Read More


Thomas Powles, MBBS, MRCP, MD, with Rohit Gosain, MD, and Rahul Gosain, MD, presenting slides

EV-302: Enfortumab Vedotin and Pembrolizumab

March 26th 2024

Read More


Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

FDA Approval of Zanubrutinib (ALPINE & SEQUOIA Study)

March 14th 2024

Read More


Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides

Updates in HR+ Breast Cancer Treatment: Expert Perspectives on CAPItello-291

February 12th 2024

Read More


Experts on lymphoma

Updates in Frontline Therapy for Lymphoma: Perspectives on the POLARIX and SWOG S1826 Clinical Trials

August 31st 2023

Read More


Key Data From EV-103: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer

Key Data From EV-103: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer

July 31st 2023

Read More


Key Takeaways From EMERALD: Elacestrant in Patients With Previously Treated ER+, HER2- Metastatic Breast Cancer

Key Takeaways From EMERALD: Elacestrant in Patients With Previously Treated ER+, HER2- Metastatic Breast Cancer

May 18th 2023

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.